Latest Conference Articles

Education could be the best resource in increasing prescription rates for clozapine.

The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.

Data show zolpidem use in 8-week insomnia trial reduced suicidal ideation in patients, even after trial randomization ended.

The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.

An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.

New data show high rate of depressive symptoms in patients with NTFE schizophrenia.

The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

Impaired reward processing could influence the presentation of sleep disturbances for patients with ADHD.

Adults often do not suffer from the symptoms of hyperactivity in ADHD.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

Data show effectiveness of DSRM in treating major depressive disorder with less frequent discontinuations.

More research is needed to fully understand the associations with different types of strabismus

Late life depression is a known risk factor for dementia, impacting 8-16% in the US.

Patients with diabetes mellitus have the highest odds of being diagnosed with an undetected eye disease.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

New data show mental health workers experienced lower levels of traumatic stress and peritraumatic distress during COVID-19 pandemic, compared to healthcare workers and general population.

Despite higher risk of adverse effects in patients with opioid use disorder, benzodiazepine does not undo protection benefits of buprenorphine.

In a poster presented at APA, researchers review current clinical practice guidelines for schizophrenia.

Allen Ho, MD, discusses the Protocol W outcomes and what they indicate for prescribing ophthalmologists.

A new study from APA 2021 finds algorithm use can reduce clinical misdiagnosis of bipolar disorder as other mood disorders, including major depressive disorder.

The rates of both diseases have been increasingly linked in recent years.

Dr. Joshua Morganstein discusses the psychological impacts disasters can have on individuals and how the COVID-19 pandemic might be different than other disasters.

The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.

An ARVO 2021 study characterizes patients with diabetic retinopathy who have also developed diabetic macular edema.

A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.